GlycoMimetics, Inc.

Good morning, and thank you for joining the GlycoMimetics Q3 2023 earnings call. At this time, all participants are in a listen-only mode. Following management's remarks, we will hold a question and answer session. At that time, lines will be open for you. If anyone should require operator assistance, please press star, then zero on your touchtone telephone. I would now like to turn the call over to Christian Deneen Long, Company Counsel at GlycoMimetics. Please go ahead.

Good morning. Today we will review our business updates and financial results for the quarter-ended September 30, 2023. The press release issued this morning is available on the company's website at glycomimetics.com. This call is being recorded. A dial-in phone replay will be available for 24 hours after the close of the call. The webcast replay will also be available for 30 days in the Investors section of the company's website. Joining me on the call today from Glycomimetics are Harit Samarjan, Chief Executive Officer, Brian Hahn, Chief Financial Officer, and Dr. Edwin Rock, Chief Medical Officer. Today's call will include forward-looking statements based on our current expectations. Forward-looking statements may include, but are not limited to, statements about the company's product candidates, UPRO-LSLN and GMI 1687, along with statements about the progress and timing of clinical trials being conducted by us or our collaborators, planned or potential regulatory agency interactions or submissions, development plans and activities, pre-launch preparations, the company's cash position and runway, and our expectations regarding data readouts from clinical trials. Such statements represent management's judgment and intention as of today and involve assumptions, risks, and uncertainties. GlycoMimetics undertakes no obligation to update or revise any forward-looking statement. For information concerning the risk factors that could affect the company, please refer to our filings with the SEC, which are available from the SEC or through the Glycomimedics website. I'll now turn the call over to Giroud.

Thank you, Christian, and good morning, everyone. In the third quarter, we continue to make strong progress advancing our clinical pipeline as we evolve into a commercial state organization. We remain committed to executing on our vision to delivery of Ploveran to AML patients in need of new treatment options while we leverage our unique glycobiology approach to develop innovative medicines in additional diseases such as sickle cell. Today, I would like to highlight three drivers that position us well to advance these programs in the coming year. First, we continue to expect top-line results from our pivotal Phase III study of UplusRand in relapsed and refractory AML by the end of Q2 2024 and remain encouraged about the unprecedented median follow-up time. Should trial results be positive, we expect US filing by end of 2024. Second, as part of our ongoing commitment to evaluate utility of UplusRand across AML, researchers from MD Anderson will present updated clinical data from their investigator-initiated trial in treated secondary AML at the American Society of Hematology meeting this December. Lastly, for GMI1687 and our sickle cell disease program, the Phase Ia study remains on track for safety data by the end of Q1 2024. With addition of the time-based analysis option to our pivotal Phase III study of uplasoran in relapse and refractory AML, we expect to report top-line results by the end of Q2 2024. We look forward to unveiling these data at this important milestone for patients, investigators, and the company. While recently FDA-approved drugs have shown encouraging results in limited AML subpopulations, we're optimistic that UplusRAN has the potential to improve patient outcomes irrespective of mutation profile, cytogenetic risk, or treatment backbones. Building on the promise of cuplaserine in relapsed and refractory AML, we are excited to explore its broader potential across different age groups and disease settings through studies run by partners and independent investigators. For example, at the upcoming ASH annual meeting in San Diego, researchers from the MD Anderson Cancer Center will present updated clinical data from their Phase 1b2 study evaluating euplaciran with cladribine and low-dose cytarabine in treated secondary AML patients. We are grateful to be collaborating with leading organizations, including MD Anderson, the National Cancer Institute, and the Dana-Farber Cancer Institute. The commitment of our partners underscores euplaciran's potential to improve and prolong lives for a broad spectrum of AML patients. We look forward to providing updates as these investigator-initiated clinical trials continue. Finally, we expect to announce safety data from our Phase 1A study of GMI1687 by end of Q1 2024. We expect these data will advance us towards our aspiration to develop GMI1687 as a patient-controlled point-of-care therapy to interrupt early sickle cell pain crisis before need to seek emergency care. We will evaluate next steps shortly thereafter. As our clinical pipeline has progressed, we have strategically expanded our commercial and medical affairs capabilities, and we are now executing critical pre-launch activities ahead of top-line euphylaxis readout expected in Q2 2024. Our educational disease awareness activities target academic and community hematologists that care for AML patients. Recently, we welcomed Dr. Gaetano Bonifacio as our Vice President of Global Medical Affairs and Deborah Peralta as our Vice President of Commercial Operations. Gaetano and Deborah bring decades of hematology launch experience, and we are pleased to have the opportunity to leverage their expertise during this transformative point in our company's evolution. Now, turning to our finances, we have a cash runway to fund operations into late Q4 2024. allowing us to continue executing our clinical development plan. On today's call, I'm happy to be joined by our CFO, Brian Hahn, and our CMO, Dr. Ed Rock. I'll now pass it over to Ed to share more details on our ongoing trials.

Thanks, Harut, and thanks to all of you on the line for joining our call today. As Harut mentioned, we expect to report top-line results of our Phase III trial by the end of Q2 2024. At that time, we'll have a clinically mature data set for time-based primary analysis of overall survival if the 295 survival events that trigger primary analysis are not already reached by that time. Median follow-up for our Phase III trial of upralesolin in relapsed and refractory AML stands now at 33 months and will be greater than three years at time of primary analysis. That's unprecedented for a therapeutic trial in relapsed and refractory AML. Also, a substantial majority of surviving study patients received hematopoietic cell transplantation, and at primary analysis, a large majority of them will be at least two years out from their transplant. After two years post-transplant, disease relapse becomes infrequent. So with at least two years of post-transplant follow-up, for almost all transplant recipients, we're confident that our time-based primary analysis will provide adequate trial duration to demonstrate uprolacilin benefit if present. Our biologic hypothesis is that adjunctive uprolacilin will lead to deeper, more durable AML disease responses that help more people to and through potentially curative hematopoietic cell transplantation. This effect may occur irrespective of specific gene mutations, cytogenetic risk, or treatment backbone. Correspondingly, uprolessal and clinical activity is seen in both newly diagnosed and relapsed and refractory AML. Importantly, uprolessal appears to generate a notably unremarkable safety profile, adding no additional toxicity when combined with other therapies. So we're optimistic that uprolacilin may one day be safely combined with diverse other therapies that are broadly useful for most or all AML patients. Partner and independent investigator studies are further exploring potential benefit of uprolacilin across AML subtypes. Most importantly, a randomized NCI Phase 2-3 trial conducted by the Alliance for Clinical Trials in Oncology is evaluating upraleslin in newly diagnosed older patients with AML who are fit for intensive chemotherapy. This trial completed phase two randomization of 267 patients in December 2021. Phase two analysis of event-free survival has been pending since then, now almost two years since enrollment completion. And NCI recently confirmed to us that the event trigger for analysis hasn't yet been reached. For reference, the Phase 2 portion of this trial was designed to demonstrate prolongation of median event-free survival from 7 to 11 months. We look forward to learning Phase 2 results when available. NCI expanded our collaboration and now also supports a children's oncology group phase one study conducted by their pediatric early phase clinical trial network. This dose escalation trial will assess safety, pharmacokinetics, and preliminary clinical activity of buprolacillin plus chemotherapy in pediatric patients with relapsed or refractory AML. We're glad to announce that the first patient enrolled to this study in October. Another investigator-initiated trial led by Dr. John Horan from the Dana-Farber Cancer Institute and Boston Children's Hospital also dosed its first patient earlier this year. Dr. Horan's trial is evaluating upralesolin with a pre-transplant regimen for pediatric and adult AML patients up to 39 years old. Today, we announced that at ASH in December, Researchers from MD Anderson Cancer Center will present updated trial data on upralesolin in treated secondary AML. This rare, very high risk study population is defined by prior chemotherapy treatment of an antecedent hematologic disorder. Prognosis is abysmal, with expected median survival of less than five months. In the trial at MD Anderson, Investigators sought to generate a safe approach to marrow blast reduction, disease control, and potential for transplant by combining upralesolin with low-intensity chemotherapy of cladribine and cytarabine. Bad prognostic features in the study population include adverse cytogenetic risk and prior hypomethylating agent use in all evaluable patients, and prior hematopoietic cell transplantation in 25% of them. Among 18 valuable patients as of data cutoff, there were minimal therapy-related toxicities, 72% showed a reduction in bone marrow blasts, and one patient had a potentially curative transplant. These results in this notoriously difficult-to-treat disease underscore broad potential utility of upraleslan across the AML spectrum. In addition, researchers from Washington University will present at ASH safety and signal-generating data from their trial of upralesolin to reduce GI toxicities of melphalan chemotherapy given before transplant for multiple myeloma. Beyond upralesolin, we also made progress in our Phase Ia single ascending dose trial of GMI1687, a second-generation E-selectin antagonist. We will evaluate GMI1687 as a potential outpatient, self-administered subcutaneous therapy to interrupt sickle cell vaso-occlusive crises. E-Selectin plays a key mechanistic role in early progression of such acutely painful pathologic events. And if successful, GMI1687 offers potential for a point-of-care, patient-controlled treatment option at time of pain onset. In addition to patient benefit from pain control, such a point of care therapy has potential to reduce emergency room visits and hospitalizations of recipients. As mentioned, we expect to have safety data in hand from this healthy volunteer study by the end of Q1 2024. Now I'll turn it over to Brian for a review of financial results.

Thank you, Ed. As of September 30, 2023, GlycoMedix had cash and cash equivalents of $49.4 million as compared to $47.9 million as of December 31, 2022. This increase was due to the company's ability to raise additional cash earlier this year. The company's research and development expenses were $5.3 million for the quarter ended September 30, 2023, as compared to $4.9 million for the same period in 2022. The increased expenses were primarily due to the clinical development costs related to the Phase 1A trial of GMI 1687 in Healthy Adult Volunteers, which was initiated in August 2023, partially offset by decreased personnel-related and stock-based compensation costs due to lower headcount. The company's general administrative expenses increased to $4.5 million for the quarter ended September 30, 2023, as compared to $3.8 million for the same period in 2022. The increased expenses were primarily due to higher personnel-related expenses and higher professional fees as the company advances UPIL-SLAN and prepares for potential regulatory filing and commercialization. I'd now like to turn the call back to Haroud.

Thank you, Brian. In summary, we are at a crucial stage in our company's evolution. In the coming months, we will remain laser-focused on delivering the data, our Phase III study of UPIL-SLAN in the relaxed and reflected AML, and continuing strategic pre-launch activities to accelerate our transition to a commercial stage company after top-line results by end of Q2 2024. We have the right team with the right experience in place, and I'm confident that we will be able to build upon our collective track record of successful commercial launches should data permit. Also, we continue to explore Eupressurant's potential across the AML spectrum thanks to studies conducted by institutions such as the NCI, Dana-Farber Cancer Institute, and MD Anderson Cancer Center. Finally, we continue to progress our phase one study of GMI 1687 towards initial data readout in Q1 2024. In closing, I want to thank our employees whose hard work and dedication drive your cholesterol forward, as well as the patients and investigators that make these trials possible. I'd now like to open the lines to Q&A. Operator?

Certainly. As a reminder, to ask a question, please press star 11 on your telephone and wait for your name to be announced. To withdraw your question, please press star 11 again. Please stand by while we compile the Q&A roster. And one moment for our first question. Our first question will be coming from Roger Song of Jefferies. Roger, your line is open.

Great, thank you. Thanks for the update. A couple questions from us. One thing is, can you share with us how likely by the end of 2Q 2024, the primary analysis will be event-based versus time-based? Just in other words, how the event accumulation since last update. Thank you.

Good morning, Roger. Excellent question. So as we have mentioned over the last year, we have seen at two stages a slowdown in the number of events, which really led us to the collaboration with the FDA and introduction of the time-based event trigger. So currently we're monitoring this very carefully, Roger, and what's happening is a lot of the patients, as we are now almost two years out from full enrollment, the follow-up a lot of the times goes into quarterly rather than monthly. So we're evaluating that over the next couple of months, and we should know better by end of year and beyond. But currently, what we are very pleased about is either through the event-based trigger or the time-based trigger, we have a definitive cutoff by end of Q2 2024. Excellent. I look forward to

the next update and also you guided you will submit the NDA by the end of this year by the end of a 2024 if the primary analysis is positive just curious any outstanding CMC or preclinical work you still need to finish before you can file the NDA or anything else you know the steps into the NDA fighting

Yeah, Roger, we're in very good shape as we have been really, you know, this trial, as you know, has taken longer than what any of us have anticipated, driven by the fact that patients continue to live longer. Meanwhile, we have done a very good job in terms of advancing CMC conversations, making sure that we have drugs. making sure that we're preparing for an NDA filing with whatever we can do before we actually see the data as we continue to be blinded to that. So we think we have the foundation for a, you know, very rapid move into an NDA filing, you know, after the data, should the data be positive. So that's why we have now in a position to say that we're going to be doing that before end of the year.

Excellent. Yeah, you do have some additional time to prepare all the work. Okay. Maybe just last one from us, if I can, is in terms of 1687, the healthy volunteer data by the end of 1Q next year. So how should we think about that data? What are you really looking for from that data to move forward, like those response or biomarker that will be helpful? Thank you.

Yeah, maybe I'll tackle some of the strategic perspective, and if you want to add a few things about what we're going to be seeing. So strategically, Roger, as you know, 1687 is our second generation. It's like the antagonist that is subcutaneously bioavailable, and that's why we're very excited to target sickle cell disease as our next area. As you know, we have a very deep tradition in that area with our first generation molecule. So, once we see, of course, the Phase 1A is really about safety. We want to make sure that we are doing all the building blocks to get to the next level. And depending on the data and depending on where we are as well with not just the 301, our company-sponsored trial, but also the NCI-sponsored Phase 2 in the frontline setting, which continues to also take longer. Depending on what happens with these, we will be in a situation to, you know, say what do we want to do next and when after that. But Ed, if you want to maybe tackle the, you know, what's the Phase Ia.

Sure. Roger, as you know, key information from any first in human trial will include safety data and pharmacokinetics. In particular, will the pharmacokinetics support achievement of a potential therapeutic level of the study drug. Based on prior glycomimetics experience, we're confident that GMI 1687 will perform and will demonstrate that and share it when available.

Awesome. That's great. Thanks for taking the question. That's it from the left.

Thank you, Roger.

Again, if you would like to ask a question, please press star one one on your telephone and wait for your name to be announced. Our next question will be coming from Boris Peeker of TD Cohen. Your line is open.

Great, thanks for taking my question. First, can you remind us, maybe I missed that, how many patients in the EUPR study went on to transplant and also what the dropout rate was?

Good morning, Boris. In which study?

in your study specifically. But I guess if you know for the NCI study as well, I guess it would be helpful for both of them.

Yeah, what we have announced, Boris, as you know, is that in our phase two trial in relapsed refractory, we had seen a 31% transplant rate. And as mentioned before, in our phase three, we are seeing a number north of that number. We have not disclosed the exact number. What we are saying is it's north of 31%. Gotcha.

And the dropout rate? Ed?

Yeah, the dropout rate is 3%. Gotcha.

That's pretty low.

I guess my last question is... It's a very low number, yes.

My last question is on the NCI study. Do you have a sense of why that's taking so long?

Yeah, I mean, we have our opinions, obviously, but, you know, we have to wait for the data to see what's happening. And as you know, the last patient enrolled in that trial in the Phase 2 population, 267th patient, was enrolled in December 2021. And that is an EFS primary endpoint for the Phase 2. So we are very intrigued and hopeful. that that's happening because events are not reaching. And if that's the case, then that's good news to patients, obviously. So we'll see. Once they reach the events, we collaborate with the NCI. We continue to have dialogues with them. And they have told us that when they get to the events, they will let us know. And until now, they have not done so.

Great. Thanks, Dave, for my questions.

Thank you, Boris.

And I'm showing no further questions at this time. I would now like to hand the call back to Haroud for closing remarks.

Thank you, operator. And thank you to everyone for joining our call today. We look forward to keeping you up to date on glycometics and seeing some of you at the Jefferies London Healthcare Conference or at the ASH in December. Thank you very much.

Ladies and gentlemen, this concludes today's conference. Thank you for your participation. You may now disconnect.